|Targets||Sphingosine-1-phosphate receptor 1(S1PR1)|
|Description||GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosphorylation. It has good oral bioavailability. It was selected as a candidate for further clinical on the basis of the favorable in vitro ADME and in vivo PK/PD properties as well as broad toxicology evaluations.|
|Solubility||10 mM in DMSO|
|Application||GSK1842799 was selected as a candidate for further clinical.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
Ceralifimod (ONO-4641) is a selective agonist of sphingosine 1-phosphate (S1P) receptor 1 and 5 (EC50 = 0.0273 and 0.334 nM). In animal experiment, ONO-4641 pre...
AKP-11 is a novel agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 with the potential to treat multiple sclerosis (MS).
GSK-2018682 is a potent and selective agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 that has the potential to treat multiple sclerosis (MS).
GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosp...
Ponesimod is an orally active and selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator that acts as a functional antagonist. It has potential imm...